Enhertu
Boehringer Ingelheim breaks into oncology as FDA grants accelerated approval to Hernexeos (zongertinib) for HER2 TKD–mutated NSCLC
Boehringer Ingelheim; Hernexeos; zongertinib; FDA approval; accelerated approval; non-squamous NSCLC; HER2 TKD mutations; Oncomine Dx Target Test; Beamion LUNG-1; objective response rate; first oral targeted therapy for HER2-mutant NSCLC; priority review; breakthrough therapy designation; confirmatory trial requirement; competition with Enhertu
AstraZeneca Beats Q2 Estimates on Strong Cancer Drug Sales
AstraZeneca; Q2 2025; cancer drug sales; oncology portfolio; Tagrisso; Imfinzi; Enhertu; financial results
AstraZeneca, Daiichi say Enhertu delivers ‘highly statistically significant’ efficacy in first-line breast cancer
Enhertu, fam-trastuzumab deruxtecan-nxki, AstraZeneca, Daiichi Sankyo, HER2-positive metastatic breast cancer, first-line therapy, progression-free survival, antibody drug conjugate (ADC), pertuzumab
FDA Approves Roche’s PATHWAY HER2 Test for HER2-Ultralow Metastatic Breast Cancer
Roche, PATHWAY HER2 (4B5) test, FDA approval, HER2-ultralow, metastatic breast cancer, companion diagnostic, Enhertu, personalized medicine
Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer
Enhertu, FDA Approval, HER2-Low, HER2-Ultralow, Breast Cancer, AstraZeneca, Daiichi Sankyo
NICE Rejects Enhertu for NHS Use Due to Pricing Stalemate with AstraZeneca and Daiichi Sankyo
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, breast cancer, pricing stalemate, NHS, England
Daiichi Sankyo and Alteogen Collaborate on Subcutaneous Enhertu Development in $300M Licensing Agreement
Daiichi Sankyo, Alteogen, subcutaneous Enhertu, $300M licensing deal, human hyaluronidase, cancer treatment
Enhertu Demonstrates Promising Efficacy in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
Enhertu, Trastuzumab Deruxtecan, HER2-positive metastatic breast cancer, brain metastases, progression-free survival, objective response rate.
NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns
NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection
AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform